1244 - Treatment Satisfaction and Adherence of Patients on Biologic Monotherapy

Monday, November 7, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
J÷rg Kaufmann1, Anne-Eve Roske2, Adrian Kielhorn2, Eugen Feist3 and Wolfgang A. Schmidt4, 1Rheumatologist, Ludwigsfelde, Germany, 2Roche Pharma AG, Grenzach-Wyhlen, Germany, 3CharitÚ Medical School, Berlin, Germany, 4Med Ctr Rheumatol Berlin Buch, Berlin, Germany
Presentation Number: 1244


The combination of a biologic DMARD (bDMARD) with methotrexate (MTX) is regarded as the gold standard for patients having not adequately responded to a conventional DMARD (cDMARD) therapy. Nevertheless, up to 40% of patients are receiving bDMARD monotherapy.

The aim is to compare treatment satisfaction and adherence in patients with rheumatoid arthritis on either TNF inhibitors or tocilizumab, both given as monotherapy.


Data from 254 patients treated with bDMARD mono-therapy (TNF inhibitor or tocilizumab) between February and June 2010 were analyzed retrospectively in 23 centers across Germany. Analysis included drug adherence over a period of six months as well as patients and physicians global assessment on a 100 mm analogue scale. Selection criteria were confirmed diagnosis of RA; age > 18 years, and treatment initiation between February and June 2010. Patients had to be on their first or second bDMARD.


Eighty-four percent of the patients were female; the mean age was 58 years (SD=18) and the mean weight was 70kg (SD 15.8). The mean time since diagnosis was 8.7 (SD 7.7) years. The tocilizumab and TNF inhibitor cohorts consisted of 126 and 128 patients, respectively.



Tocilizumab (SD)

TNF inhibitors (SD)



Percentage still on treatment after 6 months (adherence)

90% (n=113)

76% (n=97)

83% (n= 210)

Patients global assessment after 6 months

75.3 (23.0)

66.8 (23.6)

71.0 (23.6)

Physicians global assessment after 6 months

74.9 (22.8)

67.1 (23.5)

70.9 (23.5)

General Health (VAS, change from baseline)

-32.0 (23.0)

-15.3 (30.5)

-25.2 (27.4)

*0= not satisfied, 100= satisfied, SD = standard deviation

Conclusion: Biologic DMARD mono-therapy is well tolerated by patients as expressed by the high adherence rate of 83%. The adherence rate of 90% shows tocilizumab to be an attractive treatment option in these patients.

Keywords: rheumatoid arthritis (RA)

Disclosure: J. Kaufmann, Roche Pharma AG, 5 ; A. E. Roske, Roche Pharma AG, 3 ; A. Kielhorn, Roche Pharma AG, 3 ; E. Feist, None; W. A. Schmidt, Roche Pharma AG, 5 .